Dark

Check out our API

DICE
DICE Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Aug 8, 2023

47.55USD+0.063%(+0.03)4,332,950

Pre-market

0.00USD-100.000%(-47.52)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 16, 2021

04:05PM EST DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will participate in the following investor conferences in November: GlobeNewswire Inc

Nov 12, 2021

08:00AM EST -- Dosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806 -- Successfully completed $234.6 million upsized initial public offering GlobeNewswire Inc

Oct 25, 2021

08:05AM EDT DICE Therapeutics Reports Initiation Of Phase 1 Trial Of S011806 For Treatment Of Psoriasis Benzinga

08:00AM EDT DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 11, 2021

10:51AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 Benzinga

07:17AM EDT B of A Securities Initiates Coverage On DICE Therapeutics with Buy Rating, Announces Price Target of $41 Benzinga

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 15, 2021

01:07PM EDT DICE Therapeutics Shares Open For Trade At $30; IPO Priced $17/Share Benzinga

09:18AM EDT DICE Therapeutics Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced At $17/Share Benzinga

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

09:43PM EDT DICE Therapeutics Prices Upsized IPO Of 12 Mln Shares At $17.00/shr RTTNews

09:31PM EDT DICE Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire Inc

Share